Krsnaa Diagnostics Limited

rs,

D ... <1< Date: 02 nd February, 2022 BSE Ltd. Corporate Service Department pt Floor, P.J. Towers, Dalal Street, Mumbai 400 001 Scrip ID: KRSNAA Scrip Code: 543328 Dear Sir/Madam, The Nationa

29 Million

orporated Aug-21 Listing at BSE and NSE 1,900+ Diagnostics Centre 14 States Presence in India 29 Million Patients Served Since Inception Krsnaa Diagnostics is one of the fastest growing and differentiat

Rs. 396

ices at disruptive rates across various segments with a focus on Public Private Partnership model Rs. 396 Cr | 53% FY21 Revenue and Y-o-Y Growth Rs. 95 Cr | 24% FY21 EBITDA and Margins One of India’s l

53%

ptive rates across various segments with a focus on Public Private Partnership model Rs. 396 Cr | 53% FY21 Revenue and Y-o-Y Growth Rs. 95 Cr | 24% FY21 EBITDA and Margins One of India’s largest t

Rs. 95

with a focus on Public Private Partnership model Rs. 396 Cr | 53% FY21 Revenue and Y-o-Y Growth Rs. 95 Cr | 24% FY21 EBITDA and Margins One of India’s largest tele-radiology reporting hubs in Pune with

24%

on Public Private Partnership model Rs. 396 Cr | 53% FY21 Revenue and Y-o-Y Growth Rs. 95 Cr | 24% FY21 EBITDA and Margins One of India’s largest tele-radiology reporting hubs in Pune with capabil

rs 64

icrobiologists and over 2,700 qualified professionals including clinicians, technicians and operators 64% Revenue Growth CAGR FY18-21 Note: Operational KPI’s as of Dec 2021 89% Avg. EBITDA to Cash Flo

89%

echnicians and operators 64% Revenue Growth CAGR FY18-21 Note: Operational KPI’s as of Dec 2021 89% Avg. EBITDA to Cash Flow Conversion FY18-21 3 Krsnaa Competitive Advantages Sustainable busines

78%

cture, large scale of operations and cost competitiveness have resulted in strong bid-win rate of 78% in the past and trend is expected to continue ▪ Ability to quote attractive pricing at the time o

39%

Model Disruptive Pricing Stakeholder Value Creation Total Centre count increased at a CAGR of 39% from 682 in FY18 to 1,803 in FY21 Centres across India with presence in 14 States. Diagnostic

rs 2017

anges 2013 2018 2020 August 16, 2021 2011 Incorporated the Company with two radiology centers 2017 Expanded footprint Centres – 50 States – 4 2019 Expanded strategic tie-up with Private Hospita

Rs. 1,619

4+ mn X-Rays 5.4 mn Non-Covid Tests Conducted 0.9 mn Covid Tests Conducted Generating Revenue of Rs. 1,619 mn Generating Revenue of Rs. 2,346 mn Note: Pathology segment is including Covid-19 revenues (Inf

“We are well positioned to benefit from the commissioning on new centres and the meaningful contribution from these upcoming centres should be visible in the next fiscal year.”

“With a well- defined growth strategy, we expect to remain one of the fastest growing diagnostic chain in India, creating value for all stakeholders and fulfilling our mission ‘To make a difference in the healthcare diagnostic industry’.” Note: EBITDA is excluding CSR and ESOP expenses and PAT without exceptional items 24 Revenue and Segment Mix Revenue from Operations 16% Y-o-Y Revenue from Operations Breakdown (In Rs.”

“Mn) Revenue from Operations 64% CAGR Gross Profits and Margins 42% CAGR 3,965 3,472 2,092 2,584 906 1,296 61.9% 1,552 60.0% 721 79.6% 2,045 2,164 51.6% 62.3% FY18 FY19 FY20 FY21 9MFY22 FY18 FY19 FY20 FY21 9MFY22 Revenue from Operations EBITDA* and Margins 48% CAGR Profit After Tax** 89% CAGR 579 27.7% 292 32.2% 953 1,049 628 24.3% 24.0% 30.2% FY18 FY19 FY20 FY21 9MFY22”

Notes

6

Note

2

For further information please contact

1

Contact us

1

Note

• OPBDIT for comparative purposes is calculated as EBITDA divided by Revenue less Discounts and Expenses related to Fees to Hospitals and Others 14 Defined Strategy to Deliver Sustainable Long Term Growth Continue to Expand Presence across India Expand Diagnostic Services with Focus on Specialized Diagnostics Disciplined Acquisition to Expand Geographical Footprint Expand network within India, particularly in current geographies by leveraging experience of deploying and operating diagnostic centres Focus on private sector across both B2B and B2C segment by partnering with private healthcare providers, establishing standalone centres 1 Grow Digital Footprint Increase through online initiatives touch points and engagement Leverage data creating intelligent dashboard analytics capabilities by Implement artificial learning intelligence and machine 4 Enhance diagnostics like molecular and genomics capabilities in specialized Create additional centres to offer pathology services as well infr

Notes

Revenue mix is excluding Covid-19 business which contributed 11% to the Revenues * EBITDA is excluding CSR and ESOP expenses ** PAT without exceptional Items +85% YoY 3,078 9MFY22 1,661 9MFY21 Covid-19 Business (71)% YoY 1,345 9MFY21 394 9MFY22 22 9M FY2022 Performance Highlights Revenue up by 16%, EBITDA1 up by 73% and PAT2 is up by 215% Core business drives strong growth while Covid-19 contribution continues to decline ▪ Revenues up by 16%, primarily driven by growth in core business i.e Radiology and Pathology which registered a Revenue increase of 85% y-o-y, which was partially offset by decline of 71% in Covid-19 revenues ▪ Core business contribution was 89% whereas Covid-19 business contributed 11% to the total revenues in 9M FY22 ▪ Operating EBITDA1 increased by 73% to Rs. 105 crore and margins improved significantly to 30.2% as compared to 20.2% in 9M FY21. The EBITDA margin improvement was underpinned by higher number of tests and contribution from core business EBITDA and Mar

Notes

1. 2. EBITDA is excluding CSR and ESOP expenses PAT without exceptional items 23 Management Perspective Commenting on the results, Mr. Yash Mutha, Executive Director, said: “In 9MFY22, Krsnaa Diagnostics has delivered strong performance with revenues of Rs. 347 crore, an increase of 16% y-o-y. The growth was underpinned by Core Businesses which grew by 85% and partially offset by decline of 71% in Covid-19 revenues. EBITDA stood at Rs. 105 crore, a strong growth of 73% y-o-y with margins improving significantly to 30.2% as compared to 20.2% in 9M FY21. The EBITDA margin improvement was driven by higher number of tests, contribution from our Core Businesses and operational efficiencies in the business model. Similarly, Profit after tax stood at Rs. 50 crore, a growth of 215% with PAT margins of 14.1%. Furthermore, it is encouraging to see that within the first nine months of FY2022, Krsnaa has surpassed FY21 numbers in terms EBITDA and PAT. On the operational front, we continue to see v

Note

• YoY Growth is for 9MFY22 compared against 9MFY21 25 Profitability and Margins Gross Profits and Margins 49% Y-o-Y EBITDA and Margins* (In Rs. Mn) 73% Y-o-Y 1,049 2,164 1,451 526 53.7% 673 62.1% 673 63.2% 48.3% 62.3% 205 21.0% 324 29.9% 304 28.6% 606 20.2% 30.2% Q3FY21 Q2FY22 Q3FY22 9MFY21 9MFY22 Q3FY21 Q2FY22 Q3FY22 9MFY21 9MFY22 Profit Before Tax** 192% Y-o-Y 666 Profit After Tax** 215% Y-o-Y 166 14.9% 214 19.3% 228 7.4% 18.6% 71 7.1% 125 11.2% 163 14.7% 160 5.2% 33 3.2% 505 14.1% Q3FY21 Q2FY22 Q3FY22 9MFY21 9MFY22 Q3FY21 Q2FY22 Q3FY22 9MFY21 9MFY22

Notes

YoY Growth is for 9MFY22 compared against 9MFY21 Gross Profit Margins and EBITDA margins are calculated on Revenue from Operations * EBITDA is excluding CSR and ESOP expenses ** PBT / PAT without exceptional Items 26 Operational Performance Trend Core Business i.e Radiology and Pathology saw an increase in both, Number of Tests and Average Revenue Per Test in 9MFY22 Decline in average revenue per patient and per test in 9M FY22 is due to significant decline in the prices of Covid-19 tests Number of Patient (in Mn) 58% Y-o-Y Average Revenue Per Patient (in Rs) (27)% Y-o-Y 5.66 3.59 691 598 540 613 838 1.42 1.81 1.97 Q3FY21 Q2FY22 Q3FY22 9MFY21 9MFY22 Q3FY21 Q2FY22 Q3FY22 9MFY21 9MFY22 Number of Tests (in Mn) 81% Y-o-Y Average Revenue Per Test (in Rs) (36)% Y-o-Y 12.49 6.89 319 257 227 436 278 3.07 4.21 4.68 Q3FY21 Q2FY22 Q3FY22 9MFY21 9MFY22 Q3FY21 Q2FY22 Q3FY22 9MFY21 9MFY22

Notes

• • Average Revenue Per Test is calculated on Net Revenue (excluding Discounts) YoY Growth is for 9MFY22 compared against 9MFY21 27 Financial Performance Particulars (in Mn) Core Business Revenues FY2022 1,052 FY2021 788 Q3 Y-o-Y Growth (%) 33.6% Q2 FY2022 1,033 Q-o-Q Growth (%) 1.8% Nine Months FY2022 3,078 FY2021 1,661 Y-o-Y Growth (%) 85.3% Covid-19 Revenues Revenue from Operations Other Income Total Income Cost of Material Consumed Fees to Hospitals and Others Employee Expenses Other Expenses EBITDA* Margin (%) EBIT Margin (%) PAT ** Margin (%) Profit/Loss on fair value movement of CCPS Reported Profit After Tax Margin 13 1,065 43 1,108 117 274 140 229 304 28.6% 237 21.4% 163 14.7% - 163 14.7% 191 979 23 1,002 162 291 93 228 205 21.0% 131 13.1% 33 3.2% - 33 3.2%